Zanubrutinib

Introduction Overview

Generic Name

zanubrutinib

Brand Name

Brukinsa

Dosage Form

oral capsule (80 mg), oral tablet (160 mg [scored])

Drug Class

BTK inhibitors

Pharmacokinetics

Absorption:
Zanubrutinib is administered orally and demonstrates good bioavailability when taken with or without food, facilitating convenient dosing regimens. Peak plasma concentrations are typically attained within a few hours post-administration. The oral capsules (80 mg) and tablets (160 mg) deliver zanubrutinib efficiently, with flexible dosing options allowing either 160 mg twice daily or 320 mg once daily regimens. Clinical studies indicate that the presence of food has minimal effect on the extent and rate of absorption, supporting administration irrespective of meals. Factors such as gastrointestinal pH and motility may influence absorption, but no significant food-drug interactions have been observed.

Distribution:
Following systemic absorption, zanubrutinib exhibits extensive tissue distribution, reflected by a large apparent volume of distribution. It is highly protein-bound in plasma (>90%), predominantly to albumin and alpha-1-acid glycoprotein, which modulates free drug levels and pharmacological activity. Zanubrutinib effectively permeates into lymphoid tissues, relevant to its therapeutic targets in B-cell malignancies. Blood-brain barrier penetration is limited but may vary. The distribution profile supports its selective action on pathological B-cell populations while minimizing off-target effects.

Metabolism:
Zanubrutinib is extensively metabolized primarily in the liver by cytochrome P450 enzymes, with CYP3A4 playing a major role. The drug undergoes oxidative metabolism producing metabolites, some of which are pharmacologically inactive. Given its reliance on CYP3A4, concomitant administration with strong CYP3A inhibitors or inducers can significantly alter zanubrutinib plasma concentrations, necessitating dose adjustments or careful monitoring. Metabolite profiling illustrates limited formation of potentially active species, underscoring the parent compound as the primary mediator of therapeutic effects.

Elimination:
The elimination of zanubrutinib involves both hepatic metabolism and fecal excretion of metabolites, with minor renal clearance of unchanged drug. The terminal half-life ranges approximately 2-4 hours, supporting twice-daily or once-daily dosing schedules. In patients with severe hepatic impairment, systemic exposure increases markedly, prompting dose reduction recommendations. Renal impairment has limited impact on elimination. Overall, elimination pathways suggest that liver function critically influences pharmacokinetics and dose individualization is important in hepatic dysfunction to avoid toxicity.

Dosage Forms

Available Dosage Forms:
Zanubrutinib is available as oral capsules containing 80 mg of the active ingredient and oral tablets containing 160 mg. The tablets are scored to allow splitting into 80 mg doses as clinically indicated.

Dosages for Adults and Adolescents:
The recommended adult dosing regimens for zanubrutinib are 160 mg taken orally twice daily or 320 mg once daily. The choice of dosing frequency depends on clinical discretion and patient tolerance. Capsules should be swallowed whole with water and not opened, broken, or chewed. Tablets may be split along the score line but should not be crushed or chewed.

Specific Patient Populations:
Dose modifications are recommended for patients with severe hepatic impairment, where the exposure to zanubrutinib significantly increases. In such patients, dose reduction is advised to minimize the risk of adverse effects. No specific dosing adjustments are recommended for mild to moderate hepatic or renal impairment. Pediatric safety and efficacy have not been established, and zanubrutinib is not indicated for use in children.

Clinical Guidelines and Considerations:
Therapeutic monitoring during treatment involves regular blood counts due to the risk of cytopenias. Patient adherence is critical given the oral administration route. Healthcare providers should guide patients to take zanubrutinib consistently at the prescribed doses and times, and to avoid abrupt cessation without medical advice due to potential disease progression.

Mechanism Of Action

Zanubrutinib is a second-generation, highly selective, irreversible small molecule inhibitor of Bruton's tyrosine kinase (BTK), a crucial enzyme within the B-cell receptor (BCR) signaling pathway. By covalently binding to the cysteine-481 residue in BTK's active site, zanubrutinib inhibits BTK’s kinase activity, effectively blocking downstream signaling that regulates B-cell proliferation, survival, and migration.

At the cellular level, BTK inhibition by zanubrutinib leads to disruption of multiple pro-survival pathways including NF-κB, PI3K-Akt, and MAPK. The blockade of these signaling cascades induces apoptosis and halts the growth of malignant B-cells, which are pathologically overactive in diseases such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia (WM).

Compared with first-generation BTK inhibitors like ibrutinib, zanubrutinib exhibits improved selectivity and reduced off-target kinase inhibition, which translates clinically into fewer adverse events such as atrial fibrillation and bleeding complications. This superior selectivity is due to its optimized molecular structure allowing more potent and sustained BTK occupancy, enhancing therapeutic efficacy while improving safety.

Clinically, zanubrutinib's irreversible inhibition imparts durable suppression of BTK signaling, essential for long-term disease control in B-cell malignancies. Ongoing clinical trials and research demonstrate its robust antitumor activity across multiple lymphoma subtypes, confirming the mechanistic rationale and establishing it as a frontline and salvage therapy. Its molecular mechanism continues to serve as a model for targeted cancer therapy development in hematologic malignancies.

Pharmacological Actions

Irreversibly inhibits Bruton's tyrosine kinase (BTK), crucial in B-cell receptor signaling.
Blocks downstream pathways such as NF-κB, PI3K-Akt, and MAPK that promote B-cell proliferation and survival.
Induces apoptosis and inhibits proliferation of malignant B-lymphocytes.
Exhibits high selectivity for BTK, minimizing off-target kinase inhibition.
Suppresses malignant B-cell migration and adhesion by disrupting microenvironment signaling.
Provides sustained BTK occupancy, supporting durable antitumor activity.
Reduces tumor burden in various B-cell lymphomas by impairing survival signals.
Modulates immune cell function by targeting pathological B-cell populations.
Demonstrates improved safety profile compared to first-generation BTK inhibitors.
Facilitates clinical responses as monotherapy or in combination with other agents.
Supports oral administration with favorable pharmacokinetics for chronic therapy.
Mitigates disease progression via targeted kinase inhibition.
May impact cytokine production in the tumor microenvironment.
Improves hematologic parameters by controlling malignant cell growth.

Therapeutic Or Clinical Uses

Treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults.
Management of Waldenström's macroglobulinemia (WM) in adult patients.
Therapy for mantle cell lymphoma (MCL) in adults with prior treatment history.
Treatment of marginal zone lymphoma (MZL) that is relapsed or refractory after anti-CD20-based regimens.
Combination therapy with obinutuzumab for relapsed or refractory follicular lymphoma (FL) following two or more systemic treatments.
Alternative BTK inhibitor for patients intolerant or refractory to other kinase inhibitors.
Used in B-cell malignancies characterized by aberrant BCR signaling dependency.
Approved by the US FDA since 2019 for select hematological cancers.
Proven efficacy in inducing durable remission and disease stabilization.
Option for patients requiring oral targeted therapies with manageable side effect profiles.
May serve as salvage therapy for resistant B-cell lymphomas.
Potential application in clinical trials for other B-cell driven neoplasms.
Utilized in regimens to minimize chemotherapy exposure and toxicity.
Employed for maintenance therapy to prolong progression-free survival.
Suitably integrated into treatment algorithms for relapsed/refractory B-cell malignancies.

Side Or Adverse Effects

Bleeding complications including hemorrhage that can be severe and fatal.
Infections which may be serious and life-threatening, including febrile neutropenia.
Decreased blood cell counts encompassing leukopenia, thrombocytopenia, and anemia.
Secondary primary malignancies including skin cancers and other organ cancers.
Cardiac arrhythmias such as atrial fibrillation and atrial flutter.
Common adverse events like upper respiratory tract infections.
Rash presenting as mild to moderate dermatologic reactions.
Musculoskeletal pain including muscle and joint discomfort.
Bruising or increased susceptibility to bruising.
Gastrointestinal disturbances including nausea and diarrhea.
Fatigue and asthenia reported during prolonged therapy.
Headache and dizziness, potentially related to cardiovascular effects.
Rare cases of tumor lysis syndrome post-treatment initiation.
Potential hepatotoxicity in patients with impaired liver function.
Hypersensitivity or allergic reactions including infusion-related symptoms.

Precautions

Use with caution in patients with active bleeding disorders or coagulopathies.
Monitor closely if concomitant anticoagulants or antiplatelet agents are used.
Avoid use during planned surgical or dental procedures; temporary discontinuation may be required.
Careful monitoring in patients with pre-existing cardiac arrhythmias or heart rhythm disturbances.
Assess for signs of infection regularly; initiate prompt treatment if infection develops.
Regular blood count monitoring to detect and manage cytopenias early.
Dose adjustments recommended for patients with severe hepatic impairment.
Patient education on signs and symptoms of bleeding and infection is essential.
Advise on strict sun protection to reduce risk of secondary skin cancers.
Caution during pregnancy and breastfeeding due to potential teratogenicity and unknown secretion in milk.
Evaluate for potential drug interactions, especially with CYP3A4 modulators.
Alert for symptoms such as unexplained bruising, bleeding, dizziness, and unusual fatigue.
Discontinue if severe adverse effects or intolerances develop.
Screen for hepatitis B virus reactivation risk prior to initiation.
Monitor cardiac function in patients with high cardiovascular risk.

Warnings

Serious and potentially fatal hemorrhagic events can occur; bleeding risk is increased with concurrent blood thinner use.
Infections may be severe and life-threatening; vigilance for fever and infection symptoms is critical.
Risk of secondary primary malignancies during therapy necessitates regular surveillance.
Cardiac arrhythmias including atrial fibrillation and flutter have been reported; may lead to syncope or stroke.
Not established as safe or effective in pediatric populations.
Pregnancy category: Potential to cause fetal harm; effective contraception required for males and females during and shortly after treatment.
Do not breastfeed during treatment and for two weeks after the last dose due to unknown excretion in milk.
Potential for increased toxicity in hepatic impairment; dose modification required.
Abrupt discontinuation may lead to disease flare; tapering or medical guidance needed.
Possible drug interactions that can increase toxicity or reduce efficacy, especially CYP3A inhibitors/inducers.
Store at controlled room temperature away from moisture and heat.
Use child-resistant packaging to prevent accidental ingestion.
Patients should be monitored for CNS effects such as confusion or headache persisting over time.
Careful consideration required before combining with other immunosuppressants.
Close monitoring required post surgery to balance bleeding and thrombotic risks.

Contraindication

Known hypersensitivity to zanubrutinib or any of its excipients.
Active severe uncontrolled bleeding.
Concurrent use with strong CYP3A inducers that cannot be avoided.
Pregnancy due to potential teratogenicity and fetal harm.
Patients with severe hepatic impairment without dose adjustment guidance.
Known history of serious allergic reactions to BTK inhibitors.
Children and adolescents due to lack of established safety and efficacy.
Concomitant use with medications that may cause additive serious cardiac arrhythmias without close monitoring.
Use in patients with active uncontrolled infections.
Patients unable to comply with oral dosing regimen or monitoring requirements.
Patients with history of secondary malignancies unless benefits outweigh risks.
Concomitant use with other irreversible BTK inhibitors.
Concurrent administration with grapefruit or grapefruit juice, which affect CYP3A metabolism.
Known pregnancy or breastfeeding status not ruled out prior to therapy initiation.
Unmanaged cardiovascular disease posing undue risk when combined with BTK inhibition.

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) significantly increase zanubrutinib levels; dose adjustments recommended.
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce zanubrutinib efficacy by decreasing plasma exposure.
Concomitant use with blood thinners like warfarin or direct oral anticoagulants elevates bleeding risk.
Co-administration with antiplatelet agents may potentiate hemorrhagic events.
Grapefruit and grapefruit juice can increase plasma concentrations by inhibiting CYP3A4.
Use with other kinase inhibitors may increase adverse events due to additive toxicities.
Drugs that prolong QT interval require caution due to potential cardiac arrhythmia risk.
Co-administration with strong CYP3A inhibitors in patients with hepatic impairment requires careful monitoring and dose modification.
Concomitant use of immunosuppressive agents may increase infection susceptibility.
Medications metabolized by CYP3A4 may have altered pharmacokinetics when used with zanubrutinib.
P-glycoprotein substrates may interact, influencing drug absorption or clearance.
Herbal supplements such as St. John’s wort may decrease drug effectiveness by inducing CYP3A4.
Use of proton pump inhibitors or antacids does not significantly affect zanubrutinib absorption.
Caution when combined with other agents causing cytopenias to avoid exacerbated myelosuppression.
Monitoring is advised when using combination regimens including zanubrutinib to detect new or unexpected interactions.

Preparations Of The Drug

Oral capsule containing 80 mg of zanubrutinib with inactive ingredients including colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate, in a gelatin-based capsule shell colored with edible black ink and titanium dioxide.
Oral tablet containing 160 mg zanubrutinib, film-coated with components such as FD&C Blue No. 1 and No. 2, hypromellose, titanium dioxide, and triacetin for stability and ease of swallowing.
Capsules designed to be swallowed whole and not to be opened, broken, or chewed to maintain pharmacokinetics and efficacy.
Scored tablets can be split to adjust dose according to clinical guidance but should not be crushed or chewed.
Packaged in bottles featuring child-resistant caps to prevent accidental ingestion.
Stored at controlled room temperature between 20°C to 25°C (68°F to 77°F) to preserve drug potency.
Inactive ingredient lactose monohydrate present in tablets may be relevant for patients with lactose intolerance.
Manufactured and distributed by BeiGene USA, Inc. under the brand name Brukinsa.
Formulation designed for convenient oral administration facilitating chronic therapy adherence.
Contains excipients that stabilize the drug and enhance bioavailability while minimizing adverse manufacturing variabilities.
Both capsule and tablet forms support flexible dosing regimens to tailor therapy to individual patient needs.
Packaging includes detailed labeling with usage instructions and safety information.
Available formulations optimized for consistent pharmacokinetic profiles and patient tolerability.
Formulations comply with regulatory standards for oncology therapeutics regarding purity, potency, and safety.
Storage and handling guidelines included to ensure drug integrity from manufacture through to administration.